These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 36906225)

  • 1. Risk of infection in elderly patients with inflammatory bowel disease under biologics: A prospective, multicenter, observational, one-year follow-up comparative study.
    Bozon A; Nancey S; Serrero M; Caillo L; Gilletta C; Benezech A; Combes R; Danan G; Akouete S; Pages L; Bourgaux JF; Le Cosquer G; Boivineau L; Meszaros M; Altwegg R
    Clin Res Hepatol Gastroenterol; 2023 May; 47(5):102107. PubMed ID: 36906225
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative Safety and Effectiveness of Biologic Therapy for Crohn's Disease: A CA-IBD Cohort Study.
    Singh S; Kim J; Luo J; Paul P; Rudrapatna V; Park S; Zheng K; Syal G; Ha C; Fleshner P; McGovern D; Sauk JS; Limketkai B; Dulai PS; Boland BS; Eisenstein S; Ramamoorthy S; Melmed G; Mahadevan U; Sandborn WJ; Ohno-Machado L
    Clin Gastroenterol Hepatol; 2023 Aug; 21(9):2359-2369.e5. PubMed ID: 36343846
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prior Immunogenicity to Anti-TNF Biologics Is Not Associated with Increased Anti-drug Antibodies to Vedolizumab or Ustekinumab.
    Costable NJ; Borman ZA; Ji J; Dubinsky MC; Ungaro RC
    Dig Dis Sci; 2022 Jun; 67(6):2480-2484. PubMed ID: 34021427
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ustekinumab and Vedolizumab Are Equally Safe and Effective in Elderly Crohn's Disease Patients.
    Gebeyehu GG; Fiske J; Liu E; Limdi JK; Broglio G; Selinger C; Razsanskaite V; Smith PJ; Flanagan PK; Subramanian S
    Dig Dis Sci; 2023 May; 68(5):1983-1994. PubMed ID: 36436155
    [TBL] [Abstract][Full Text] [Related]  

  • 5. No Benefit of Concomitant Immunomodulator Therapy on Efficacy of Biologics That Are Not Tumor Necrosis Factor Antagonists in Patients With Inflammatory Bowel Diseases: A Meta-analysis.
    Yzet C; Diouf M; Singh S; Brazier F; Turpin J; Nguyen-Khac E; Meynier J; Fumery M
    Clin Gastroenterol Hepatol; 2021 Apr; 19(4):668-679.e8. PubMed ID: 32629124
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative risk of serious infections and tuberculosis in Korean patients with inflammatory bowel disease treated with non-anti-TNF biologics or anti-TNF-α agents: a nationwide population-based cohort study.
    Kim MJ; Kim YJ; Jeong D; Kim S; Hong S; Park SH; Jo KW
    Therap Adv Gastroenterol; 2024; 17():17562848241265013. PubMed ID: 39092170
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effectiveness of vedolizumab and ustekinumab as second biologic agent in achieving target outcomes in tumor necrosis factor antagonists experienced patients with inflammatory bowel disease (enroll-ex study).
    Alrashed F; Abdullah I; Alfadhli A; Shehab M
    Front Pharmacol; 2023; 14():1243080. PubMed ID: 37876726
    [No Abstract]   [Full Text] [Related]  

  • 8. Comorbidity, not patient age, is associated with impaired safety outcomes in vedolizumab- and ustekinumab-treated patients with inflammatory bowel disease-a prospective multicentre cohort study.
    Asscher VER; Biemans VBC; Pierik MJ; Dijkstra G; Löwenberg M; van der Marel S; de Boer NKH; Bodelier AGL; Jansen JM; West RL; Haans JJL; van Dop WA; Weersma RK; Hoentjen F; Maljaars PWJ;
    Aliment Pharmacol Ther; 2020 Oct; 52(8):1366-1376. PubMed ID: 32901983
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and effectiveness of ustekinumab in elderly Crohn's disease patients.
    Fiske J; Liu E; Limdi JK; Conley TE; Townsend T; Davies M; Brockwell R; Baig D; Abdelbadiee S; Uney A; Liaros A; Gaba W; Smith PJ; Flanagan PK; Subramanian S
    Eur J Gastroenterol Hepatol; 2022 Nov; 34(11):1132-1139. PubMed ID: 36170682
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparing Patient-Reported Outcomes Among Anti-TNF-Experienced Patients with Crohn's Disease Initiating Vedolizumab Versus Ustekinumab.
    Kappelman MD; Lewis JD; Zhang X; Lin FC; Weisbein L; Chen W; Burris J; Dorand JE; Parlett LE; Haynes K; Nair V; Kaul AF; Dobes A; Long MD
    Dig Dis Sci; 2023 Aug; 68(8):3413-3420. PubMed ID: 37115362
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biologics and 30-Day Postoperative Complications After Abdominal Operations for Crohn's Disease: Are There Differences in the Safety Profiles?
    Lightner AL; McKenna NP; Alsughayer A; Harmsen WS; Taparra K; Parker ME; Raffals LE; Loftus EV
    Dis Colon Rectum; 2019 Nov; 62(11):1352-1362. PubMed ID: 31567927
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comorbidity Influences the Comparative Safety of Biologic Therapy in Older Adults With Inflammatory Bowel Diseases.
    Cheng D; Kochar B; Cai T; Ritchie CS; Ananthakrishnan AN
    Am J Gastroenterol; 2022 Nov; 117(11):1845-1850. PubMed ID: 35854436
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ustekinumab and Vedolizumab Are Not Associated With Subsequent Cancer in IBD Patients with Prior Malignancy.
    Hong SJ; Zenger C; Pecoriello J; Pang A; Vallely M; Hudesman DP; Chang S; Axelrad JE
    Inflamm Bowel Dis; 2022 Dec; 28(12):1826-1832. PubMed ID: 35262671
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prevalence of Immunomodulator Use as Combination Therapy With Vedolizumab or Ustekinumab in Inflammatory Bowel Disease.
    Lutz M; Caldera F; Schroeder K; Gazis D; Crawford JM; Long MD; Barnes EL
    Clin Transl Gastroenterol; 2023 Nov; 14(11):e00620. PubMed ID: 37450671
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative Safety of Ustekinumab and Vedolizumab in Older Patients with Inflammatory Bowel Disease: A Bicentric Cohort Study.
    Burgevin A; Caron B; Sasson A; Luc A; Netter P; Baumann C; Ananthakrishnan AN; Peyrin-Biroulet L
    J Clin Med; 2022 Nov; 11(23):. PubMed ID: 36498541
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ustekinumab and vedolizumab for extraintestinal manifestations in inflammatory bowel disease - a retrospective study.
    Livne-Margolin M; Ling D; Attia-Konyo S; Abitbol CM; Haj-Natour O; Ungar B; Ben-Horin S; Kopylov U
    Dig Liver Dis; 2023 Feb; 55(2):223-229. PubMed ID: 36241535
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment persistence of ustekinumab and vedolizumab in IBD patients is independent of prior immunogenicity to anti-TNFs: a retrospective study.
    Blesl A; Petritsch W; Binder L; Fürst S; Wenzl H; Baumann-Durchschein F; Kump P; Högenauer C
    Scand J Gastroenterol; 2022 Nov; 57(11):1327-1330. PubMed ID: 35732583
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effectiveness, safety, and drug sustainability of biologics in elderly patients with inflammatory bowel disease: A retrospective study.
    Hahn GD; LeBlanc JF; Golovics PA; Wetwittayakhlang P; Qatomah A; Wang A; Boodaghians L; Liu Chen Kiow J; Al Ali M; Wild G; Afif W; Bitton A; Lakatos PL; Bessissow T
    World J Gastroenterol; 2022 Sep; 28(33):4823-4833. PubMed ID: 36156919
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ustekinumab does not increase risk of new or recurrent cancer in inflammatory bowel disease patients with prior malignancy.
    Hasan B; Tandon KS; Miret R; Khan S; Riaz A; Gonzalez A; Rahman AU; Charles R; Narula N; Castro FJ
    J Gastroenterol Hepatol; 2022 Jun; 37(6):1016-1021. PubMed ID: 35191100
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Infectious risk of vedolizumab compared with other biological agents in the treatment of inflammatory bowel disease.
    Innocenti T; Roselli J; Lynch EN; Apolito P; Parisio L; Bagnoli S; Macrì G; Rogai F; Tarocchi M; Milani S; Galli A; Milla M; Dragoni G
    Eur J Gastroenterol Hepatol; 2021 Dec; 33(1S Suppl 1):e574-e579. PubMed ID: 35048649
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.